Why Morgans just put buy ratings on these ASX stocks

The broker thinks these stocks could rise 17% to 68%.

Key points
  • Navigator Global's strategic aim to double EBITDA over five years highlights its pursuit of strong growth potential, even as shares remain attractively priced at 13 times future earnings.
  • Polynovo's revamped leadership and promising trading updates are breathing new life into this medical tech company, paving the way for impressive sales growth.
  • With the ASX displaying volatility, these stocks stand out due to resilient earnings and strategic positioning, according to Morgans.

Looking for new additions to your investment portfolio this month? If you are, it could pay to listen to what analysts at Morgans are saying about the ASX stocks in this article.

They have just been given buy ratings and are tipped to rise meaningfully from current levels. Here's what the broker is saying about them:

A smiling woman holds a Facebook like sign above her head.

Image source: Getty Images

Navigator Global Investments Ltd (ASX: NGI)

Morgans believes that this alternative asset management company's shares are undervalued.

It highlights that despite rising over 70% this year, its shares are still trading at just 13x estimated FY 2026 earnings.

This comes at a time when management is aiming to double its earnings over the next five years, which implies a compound annual growth rate (CAGR) of 15%. It said:

Navigator Global Investments (NGI) is an alternative asset management firm focused on partnering with leading global alternative managers, with exposure to 11 boutique firms across hedge funds, private markets, structured credit, macro, commodities and derivatives. NGI operates a simple and effective model: it takes minority stakes in high-quality, high-margin alternative managers and supports their growth with capital and strategic services. The model creates a highly diversified earnings base with strong growth potential through adding scale (new partnerships) to the existing platform.

NGI has a strategic ambition to double EBITDA over five years, implying ~15% CAGR. We believe the business has the operating structure and expertise, is self-funding, and has a large addressable market for acquisitions to achieve this target. Earnings resilience is a key feature supported by high diversity in its Assets under management (AUM) across asset classes, managers, investment strategies, and investor channels. At ~13x FY26F PE, we see this earnings durability and growth potential as undervalued.

Morgans has initiated coverage on the ASX stock with a buy rating and $3.45 price target. This implies potential upside of 17% for investors from current levels.

Polynovo Ltd (ASX: PNV)

Another ASX stock that Morgans has put a buy rating on is Polynovo.

It is a medical technology company aiming to simplify the management of acute complex wounds with its NovoSorb BTM product. This is a dermal scaffold for the regeneration of the dermis when lost through surgery, trauma or burn.

Morgans has turned more positive on the company after it strengthened its board and finally appointed a new leader. It was also pleased to see that its recent trading update suggests that the company is on to achieve its revenue forecast in FY 2026. It said:

Following changes to its Board and with the appointment of a new CEO, we see more stability and focus returning to the PNV business. The 1Q26 trading update sees group sales up 33% and gives us confidence our full-year revenue forecast (up ~17%) is on track. We sit below revenue consensus but in line with EBITDA. We have made no changes to forecasts. However, we have removed our discount to the target price which now sits at A$2.03 (was A$1.69). We have moved our recommendation up to BUY from SPECULATIVE BUY.

As mentioned above, Morgans has a buy rating and $2.03 price target on its shares. This suggests that upside of 68% is possible between now and this time next year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended PolyNovo. The Motley Fool Australia has recommended PolyNovo. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

An unhappy man in a suit sits at his desk with his arms crossed staring at his laptop screen as the PointsBet share price falls
Broker Notes

BHP, Westpac, CSL shares: Buy, sell, or hold?

One of these ASX shares is tipped to fall 13%.

Read more »

Woman tying up her shoelaces before a run.
Broker Notes

Buy, hold, sell: Coles, Wesfarmers, CSL shares

It's a new week and we've got new ratings from the experts.

Read more »

a man in a business suite throws his arms open wide above his head and raises his face with his mouth open in celebration in front of a background of an illuminated board tracking stock market movements.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Two male ASX investors and executives wearing dark coloured suits sit at a table holding their mobile phones discussing the highest trading ASX 200 shares today
Broker Notes

Buy, hold, sell: Resmed, Goodman Group, CBA shares

We review three fresh buy, hold, and sell calls from John Athanasiou at Red Leaf Securities.

Read more »

colleagues on a lunch break looking at iPhone
Broker Notes

Top brokers name 3 ASX shares to buy now

Here's what brokers are recommending as buys this week.

Read more »

Woman with her fingers crossed and eyes shut.
Broker Notes

7 ASX 200 shares in the buy zone as optimism returns to the market: experts

Brokers reaffirmed their buy calls on Liontown, Rio Tinto, Xero, and others this week.

Read more »

ASX shares broker ratings represented by three different coloured buttons.
Broker Notes

6 ASX shares upgraded and downgraded by the experts this week

Brokers have changed their ratings and 12-month price targets on Qantas, Codan, and others. 

Read more »

A woman sits in a cafe wearing a polka dotted shirt and holding a latte in one hand while reading something on a laptop that is sitting on the table in front of her
Broker Notes

Buy, hold, sell: CSL, NextDC, PLS shares

Mark Elzayed from Vestra Capital explains his ratings on three ASX 200 shares.

Read more »